Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Roivant Sciences Ltd.

Roivant Sciences Ltd. (ROIV) Stock Overview

Explore Roivant Sciences Ltd.’s financial performance, market position, analyst ratings, and future outlook.

ROIV●NASDAQ
HealthcareBiotechnology
$39.53
$0.46(1.15%)
U.S. Market opens in 39h 58m

Roivant Sciences Ltd. (ROIV)

Meyka AI Score

Z

Key Financials

Market Cap28.6B
P/E Ratio-81.98
EPS (TTM)$-1.05
ROE-0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$40.13
3 Months$45.44
1 Year Target$44.57

ROIV Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Roivant Sciences Ltd. (NASDAQ: ROIV) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Roivant Sciences Ltd.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ROIV on the NASDAQ shows an RSI of 56.70, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $44.57 for the NASDAQ listing.

Key metrics behind Roivant Sciences Ltd.'s NASDAQ-traded stock include a P/E ratio of -81.98 and a market capitalization of 28.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ROIV on the NASDAQ.

Price Performance (NASDAQ: ROIV)

1-Day Change
-1.15%
5-Day Change
7.24%
1-Month Change
18.53%
3-Month Change
8.96%
6-Month Change
35.28%
Year-to-Date (YTD) Change
82.17%
1-Year Change
92.27%
3-Year Change
336.80%
5-Year Change
389.23%
All-Time (Max) Change
280.10%

Contact Information

https://roivant.com
44 2074 003 347
50 Broadway, London, GL, SW1H 0DB

Company Facts

7,210 Employees
IPO DateDec 8, 2020
CountryGB
Actively Trading

Frequently Asked Questions